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Abstract 
Background: Over the past decades, both critical care and cancer care have improved 
substantially. Due to increased cancer-specific survival [1], we hypothesized that both the 
number of cancer patients admitted to the ICU and overall survival have increased since the 
millennium change. 
Patients and methods: MIMIC-III, a freely accessible critical care database of Beth Israel 
Deaconess Medical Center, Boston, USA [2] was used to retrospectively study trends and 
outcomes of cancer patients admitted to the ICU between 2002 and 2011. Multiple logistic 
regression analysis was performed to adjust for confounders of 28-day and 1-year mortality.  
Results: Out of 41,468 unique ICU admissions, 1,100 hemato-oncologic, 3,953 oncologic and 
49 patients with both a hematological and solid malignancy were analyzed. Hematological 
patients had higher critical illness scores than non-cancer patients, while oncologic patients had 
similar APACHE-III and SOFA-scores compared to non-cancer patients. In the univariate 
analysis, cancer was strongly associated with mortality (OR= 2.74, 95%CI: 2.56, 2.94). Over the 
10-year study period, 28-day mortality of cancer patients decreased by 30%. This trend 
persisted after adjustment for covariates, with cancer patients having significantly higher 
mortality (OR=2.63, 95%CI: 2.38, 2.88). Between 2002 and 2011, both the adjusted odds of 28-
day mortality and the adjusted odds of 1-year mortality for cancer patients decreased by 6% 
(95%CI: 4%, 9%). Having cancer was the strongest single predictor of 1-year mortality in the 
multivariate model (OR=4.47, 95%CI: 4.11, 4.84). 
Conclusion: Between 2002 and 2011, the number of cancer patients admitted to the ICU 
increased steadily and significantly, while longitudinal clinical severity scores remained overall 
unchanged. Although hematological and oncological patients had higher mortality rates than 
patients without cancer, both 28-day and 1-year mortality decreased significantly and faster than 
those of non-cancer patients over the 10-year study period. 
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Key message: Admission of cancer patients doubled between 2002-2012. Cancer patients had 
higher 28-day mortality rates than non-cancer patients (28.6% vs. 12.8%). While 28-day 
mortality rates of cancer patients decreased by 31%, clinical severity scores remained 
unchanged. After adjusting for confounders, there was an annual 6% decrease in the odds of 
dying at both 28-days and 1-year among cancer patients.  
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Background 
Cancer is a global public health concern and the second leading cause of death in the United 
States and most developed countries [3]. Despite a slight decrease in cancer incidence over the 
last two decades, cancer prevalence continues to increase due to improved treatment and 
earlier diagnosis [4].  
Historically, advanced or end-stage oncological and hematological patients were, due to their 
limited prognosis, frequently not referred to intensive care units. Novel and more efficient anti-
neoplastic treatments have resulted in prolonged progression-free and overall survival of 
oncological and hemato-oncological patients [3]. Consequently, a growing number of cancer 
patients is at risk of admission to intensive care units [1]. 
Concurrently, the average prognosis of oncological patients remains less than that of the 
general population, thereby frequently resulting in controversy whether an ICU admission is an 
appropriate medical choice [1]. While several studies have described the characteristics of 
oncological patients admitted to ICU, only two studies have investigated trends in hematological 
and oncological ICU admissions in the UK [5] and hematological patients in the Netherlands [6].  
In both settings, the absolute number of oncologic patients admitted to intensive care units has 
increased. In the Netherlands, the odds of admission increased by an annualized 6% between 
2004 and 2012, while the proportion of oncological patients admitted to British ICUs remained 
almost unchanged between 1997 and 2013. Of note, the Acute Physiology and Chronic Health 
Evaluation (APACHE-II) score for hematological patients at admission were the same in the 
Dutch and British cohorts (24 points). At the same time, both hospital (47% vs. 54%) and ICU 
mortality (34% vs. 41%) were approximately 7 percentage-points lower in the Dutch ICU cohort 
compared to the UK cohort, possibly indicating differences in referral pattern, aggressiveness of 
treatment or other patient characteristics. In both cohorts, hospital and ICU mortality for 
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hematological patients decreased, while mortality rates of oncological patients did not change. 
Regardless, the average prognosis of oncological patients remains less than that of the general 
population. For instance, hematological patients in the Netherlands had twice as high ICU 
mortality rates than patients without malignancy (34% vs. 17%).  
While prior studies have described oncological patient characteristics and outcomes in the U.S. 
[7], no published longitudinal analysis for trends in ICU mortality for the US is available. In the 
following, we therefore aim to describe trends in admission numbers and patient characteristics 
for cancer patients admitted to the ICU. Furthermore, we aim to establish if 28-day and 1-year 
mortality changed over the 10-year period, after adjusting for covariates. 
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Methods 
Patient information was extracted from a de-identified version of the MIMIC-III (v1.4) database 
using PostgreSQL (The PostgreSQL Global Development Group, https://www.postgresql.org). 
MIMIC-III is an open-access ICU database jointly administered by the Massachusetts Institute of 
Technology and the Beth Israel Deaconess Medical Center [2]. The database comprises over 
58,000 hospital admissions for 38,645 adults and 7,875 neonates, spanning from June 2001 - 
October 2012. Year of admission is not available in this limited, de-identified dataset due to 
privacy concerns. Therefore, we obtained a supplementary dataset from the administrators. 
Previously established  code from the MIMIC Code Repository was used to generate 
comorbidity scores and risk scores [8].  
A waiver of consent that has previously been obtained from the Institutional Review Boards of 
BIDMC and MIT is applicable to these datasets.  
 
Cohort Selection  
All adult patients aged 18 years or older with a diagnosis of any cancer type as identified by 
ICD-9 codes 140-199 (solid malignancies) and 209.0-3 (neuroendocrine carcinomas) or 200-
208 (hematological malignancy) were included in this study. Patients with incomplete data on 
admission year, length of stay or severity of illness were excluded during data analysis. Since 
no complete annual data for 2001 and 2012 was available, all patients admitted in this period 
were excluded from the base population. If patients were admitted multiple times to the ICU, 
only their first admission was used for this analysis.  
 
Covariates 
Patient data on the following variables were extracted from the database: 
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Age at admission, gender, race, Elixhauser Comorbidity Index scores [9], vasopressor duration, 
ventilation duration, OASIS scores [10], SOFA scores [11], APACHE-III scores [12], renal 
replacement therapy, do not resuscitate order (DNR) at admission, ICU mortality, mortality (from 
the Social Security death records). SOFA scores were interpreted as being low (0-5), medium 
(6-10) and high risk (≥11 points), respectively. Duration of ventilation and duration of 
vasopressor use were converted from continuous to binary variables. Race was categorized into 
a white and non-white category.  
Cancer diagnoses were clustered according to ICD-9 codes into: Oral malignancies (1400-
1499), gastrointestinal (1500-1599), respiratory and thoracic (1600-1659), Connective tissue 
malignancy and others (1700-1769, 17300-17399), genitourinary (1800-1899), other solid 
malignancies (1900-1992, 20900-20936), lymphoma (20000-20208, 20270-20288), leukemia 
(20310-20892), other hematologicalmalignancies (20210-20268, 20302-20382, 20290-20302) 
and metastatic cancer (1960-1991,20970-20975). 
 
Outcomes 
The primary study outcomes were (a) trends in the number and relative frequency of oncological 
patients admitted to the ICU and (b) all-cause mortality within 28 days and 1 year after ICU 
admission. Secondary outcomes were (a) hospital and ICU length of stay, (b) changes in clinical 
severity scores and (c) predictors of mortality. 
 
Statistical Analysis 
All analyses were performed using the open-access software R (version 3.4.2, http://www.R-
project.org/) and the following packages: tableone, ggplot2, dplyr, MIMICbook, epitools, sjplot, 
MASS. For table 1, chi-square testing was performed for categorical variables (with continuity 
correction) and one-way ANOVA for parametric continuous variables. Multiple logistic 
regression was used to adjust for covariate levels in the longitudinal trend analysis for 28-day 
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and 1-year mortality (categorical outcome). Model building was based on expert opinion 
including the most important confounders (C.M.S.& L.A.C.). An alpha-level of 0.05 was used as 
the cutoff value to reject the null hypotheses. Collinearity analyses were performed, hence only 
APACHE-III scores were included in the final model. We checked the final model for interaction 
terms, however did not find any interaction terms that were statistically significant after 
Bonferroni adjustment.   
 
Reproducibility 
Both the code for the SQL queries and data analysis will be made freely publicly available after 
acceptance of this article for publication. Due to privacy concerns, the re-identified data on year 
of admission will not be made publicly available. 
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Results 
By restricting our analysis to the first ICU stay for each patient, a total unique patient cohort of 
41,468 ICU admissions was obtained. Of these, 3953 had an oncologic malignancy, 1100 had a 
hematological malignancy and 49 patients had a diagnosis of both a hematological and solid 
malignancy (fig. 1).  
Baseline patient characteristics differed considerably between all subgroups (table 1). 
Hematological patients had highest mean clinical severity scores and a higher rate of DNR 
orders on admission (p<0.001), however were less likely to be ventilated or to receive 
vasopressors (p<0.001). Furthermore, mean length of ICU and hospital stay for hematological 
patients was significantly longer than that of non-cancer patients (p<0.001). Oncological 
patients had patient characteristics that were more similar to those of non-cancer patient, having 
comparable clinical severity scores and only slightly longer length of ICU and hospital stays. Of 
note, oncological patients less frequently received vasopressin and ventilation.  
Between 2002 and 2011, the overall number of patients admitted to the ICU increased from 
3110 to 5076. Over the same period, the number of patients with cancer more than double from 
285 to 678 (Suppl. table 1) and 28-day mortality of cancer patients decreased from 36.1% in 
2002 to 24.8% in 2002 (p<0.001). Concurrently, use of vasopressors (p=0.002) and ventilation 
(p<0.001) decreased significantly, while clinical severity scores did not change significantly, and 
comorbidity scores increased from 16 to 20 (p<0.001).  
Between 2002 and 2011, both crude 28-day and 1-year mortality rates decreased (fig. 2). The 
highest mortality rates were measured in the oncology group, with 27.7% and 52.6% at 28 days 
and 1 year, respectively. Over the study period, the highest relative decrease in the odds of 
death at 28 days was recorded in the hematological group (-55%), followed by the oncologic (-
40%) and non-cancer patients (-20%). There was considerable variation in 28-day mortality 
rates depending on cancer subtype, with other oncological cancers (including neuroendocrine 
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carcinomas) and cancer of the lip, oral cavity and pharynx having the highest mortality rate. 
Genitourinary and connective tissue (including breast) cancers had the lowest mortality rates of 
all malignancies. Mortality rates were closely associated with clinical severity scores across all 
cancer subtypes. Of note, patients with high SOFA-scores (≥11) and a connective tissue 
malignancy (including breast cancer, N=2) or genitourinary cancer (N=7) had a 100% probability 
of dying at 28-days. Similarly, patients with gastrointestinal cancer (N=49) or leukemia (N=23) 
and high SOFA-scores (≥11) had a close to 100% probability of dying within 1-year of ICU 
admission (Supp. Fig. 1).   
Multivariate logistic regression analysis confirmed the observed trends in mortality. For the 
whole ICU cohort, a do-not-resuscitate order at admission, any type of cancer and year of 
admission were the strongest predictors of both 28-day and 1-year mortality rates after 
adjustment for covariates (suppl. fig. 2). A DNR order was associated with a 3.69-times higher 
odds (95%CI: 3.30, 4.13) of death within 28 days of admission, and a malignancy with a 2.62 
(95%CI: 2.38, 2.88) times higher odds of death. Notable differences between the intensive care 
units exists, with the cardiac surgery recovery unit being associated with the lowest odds of 
dying (0.2, 95%CI: 0.17, 0.23), while admission to a trauma surgical unit was associated with a 
1.25 (95%CI: 1.10, 1.43) higher odds of death. Having any malignancy was the strongest single 
predictor of 1-year mortality after adjustment for covariates with an odds ratio of death of 4.47 
(95%CI: 4.12, 4.85). The observed protective association between admittance to the cardiac 
surgery recovery unit persisted (OR= 0.23, 95%CI: 0.21, 0.26). The odds of death decreased by 
an annualized 6% (95%CI: 5%, 7%) each year. (suppl. fig. 2) 
Among cancer patients, a DNR order is the single most important factor associated with both 
28-day and 1-year survival after adjustment for covariates (fig. 3). For 28-day survival, being 
ventilated (OR=2.12, 95%CI: 1.78, 2.52) or receiving vasopressors (OR=1.41, 95%CI: 1.16, 
1.70) is strongly associated with worse outcome. Noteworthily, this association is weaker for 1-
12 
year survival, with vasopressor use (OR=1.27, 95%CI: 1.06, 1.52) being weakly associated and 
ventilation (OR=1.07, 95%CI: 0.91, 1.24) not being statistically significantly associated. Both 
Apache-III score and Elixhauser comorbidity score are important predictors of survival. Patients 
in the lowest Apache-III score quartile (score=31) have a 2.0-times higher odds of dying than 
patients in the 3rd Apache-III score quartile (score=55). Similarly, patients in the lowest 
Elixhauser score quartile (score=10) have a 1.7-times higher odds of dying than patients in the 
3rd Elixhauser score quartile (score=28). Of note, white race is weakly associated with higher 
survival at 1-year (OR=0.82, 95%CI: 0.70, 0.97), but not with 28-day (OR=0.93, 95%CI: 0.77, 
1.11). For both 28-day and 1-year survival, admission to a surgical, trauma surgical or cardiac 
surgery ICU is associated with a significantly decreased odds of death compared to admission 
to a medical ICU. 
Over the 10-year study period, both 28-day and 1-year mortality decreased at an annualized 
rate of 6%. Between 2002 and 2011, the odds of dying decreased by 49.2% (28-day mortality, 
95%CI: 31%, 62%) and 44.7% (1-year mortality, 95%CI: 28%, 59%).  
 
Discussion 
This is one of the largest studies investigating trends in patient characteristics and outcomes of 
oncological patients admitted to the ICU worldwide, and the first study from the U.S. More than 
58,000 ICU admissions were analyzed and 41,468 patients were included in the final analysis, 
among which were 1100 hematological and 3953 oncological patients. Cancer patients had 
comparable clinical severity scores compared to non-cancer patients, yet were more likely to die 
within 28 days (RR=2.23) and within 1 year (RR=2.58). Mortality rates decreased significantly 
over the study period (-7% annual decrease) for all patients, with cancer patients having a 
bigger decrease in mortality rates than non-cancer patients. 
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Our findings confirm the previously reported decrease in mortality rates observed in the UK [5] 
and the Netherlands [13] since the millennium change. Interestingly, we observed unchanged 
clinical severity scores over time, while mortality rates decreased substantially between 2002 
and 2011. While 28-day survival of oncological patients (71.1%) was comparable with 30-day 
survival in the Dutch cohort (73.1%), survival of hematological patients (72.3%) differed 
considerably from the Netherlands (55%).  
As expected, clinical severity scores were strong predictors of survival, as were the presence of 
any malignancy, a DNR order at admission, type of ICU, use of vasopressors or mechanical 
ventilation and comorbidities, thereby confirming earlier studies [5, 7, 14-18]. Of note, crude 1-
year mortality rates for patients with high SOFA scores and gastrointestinal, genitourinary, 
connective tissue cancer, leukemia, lymphoma or other solid cancers were exceeding 90%. 
Mortality rates differed considerably between the ICU types and are possibly explained by 
different reasons for admission and long-term prognosis. The notable protective effect observed 
for cardiac surgical patients could be explained by selection bias, since primarily patients with a 
favorable oncologic diagnosis might undergoing surgery. In contrast, medical ICU patients might 
more likely be admitted due for reasons directly related with their underlying disease or 
treatment complications.  
Clinicians are frequently faced with the difficult decision whether patients with serious chronic 
conditions that limit their life expectancy should be admitted to the intensive care unit. This is 
particularly challenging for oncological patients, where long-term survival might more depend on 
their underlying malignancy than their acute health problem. Our findings together with 
previously published results [14, 16, 19, 20] suggests that elderly patients with high clinical 
severity scores, multiple comorbidities and certain cancer types do not sustain long-term 
survival regardless of intensive treatment. Concurrently, the presence of any malignancy alone 
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is an insufficient predictor of both 28-day and 1-year mortality and treatment decisions should 
not be based on oncological prognosis alone.  
Analysis of over 40,000 admitted patients, including more than 5,000 (hemato-)oncological 
patients allowed for precise and stratified analysis of patient characteristics, outcomes and 
predictive factors. Data was retrieved from clinical databases that were compiled at the time of 
treatment, thereby minimizing bias that may occur due to the retrospective study design. The 
high resolution of the clinical data is another advantage of this study. Furthermore, we had 
sufficient statistical power to detect annual changes in mortality of cancer patients.   
Major limitations of this study are a lack of important oncological predictive factors, including 
TNM classification, tumor size, histopathological features and clinical aggressiveness. 
Furthermore, no data was available on critically ill patients who were not admitted to the ICU 
and abstained. Preferably, additional information on oncological treatment, treatment type and 
time since administration of chemotherapy should be included in the analysis. In addition, data 
on rare cancers (including oral cancer and respiratory cancers) was sparse, thus not allowing 
for a more detailed subgroup analysis. Another disadvantage is that data was obtained from a 
single-center teaching hospital and generalizability of findings might therefore be limited. Future 
analyses should preferably include larger cohorts from different hospitals across the United 
States and contain more oncologic outcomes measures.  
Regardless of these shortcomings, the unchanged clinical severity scores over time and results 
of the multivariate logistic regression suggest that survival of oncologic patients has increased 
between 2002-2011 and is not due to confounding by other variables or selection bias. It is 
tempting to speculate that the absolute and relative increase in cancer patients admitted to the 
ICU could be interpreted as a consequence of better oncological survival, rendering more 
patients at risk of ICU admission. The alternative, namely that the observed increase in 
oncological patient admissions is due to a more lenient ICU admission policy, is not supported 
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by unchanged clinical severity scores, increased comorbidity scores and another study showing 
a decrease in ICU utilization among cancer patients between 2002-2013 [7]. Interestingly, 28-
day mortality for both cancer and non-cancer patients decreased approx. equally on the 
multiplicative scale (-6% annually). At the same time, the absolute improvement in survival is 
larger for cancer patients, due to an approx. three times higher mortality rate at baseline. 
In this descriptive study, which should not be interpreted as a prognostic survival model, we 
recorded a steady and significant increase in the number and proportion of cancer patients 
admitted to the ICU, unchanged clinical severity scores, increased comorbidity score and a 
major decrease in mortality rates between 2002 and 2011. In our multivariate model for the 
whole ICU cohort, the presence of any malignancy was the single strongest predictor of 1-year 
survival of all ICU patients.  
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Legend to the figures 
 
Figure 1: Overview of the cohort building process. Restriction to the years for which 
complete follow-up data is available decreased the cohort by 5,009 individuals. A total of 5,102 
patients with cancer were identified, of which 3,953 had an ICD-9 code of a solid tumor, 1,100 of 
a hematological malignancy and 49 both a hematological and solid malignancy.  
 
Figure 2: Changes in 28-day mortality for (A) solid malignancies and (B) hematological 
malignancies over the 10-year period. There are notable differences in mortality between the 
subgroups, with cancers of the oral cavity/lip/pharynx and other primary origin having the 
highest mortality rates. Genitourinary (GU) and breast/connective tissue had the lowest mortality 
rates. GI: gastrointestinal cancer, Oral: cancer of the oral cavity/ lip/ pharynx 
 
Figure 3: Results of the multivariate regression model for (A) 28-day and (B) 1-year 
mortality among cancer patients. (A) DNR at admission (OR=3.4) was the strongest single 
predictor of 28-day mortality after adjusting for covariates. Any use of vasopressors or 
mechanical ventialtion was associated with worse 28-day outcomes. Year of admission was a 
strong predictive factor, with the odds of dying within 28-days decreasing by 7% every year. 
Elixhauser and Apache-III scores were singificantly associated with both 28-day and 1 year 
mortality, e.g. a 1 point increase in APACHE-III increasing the odds of dying within 28 days by 
4%. Admission to a ICU other than the medical was associated with increased survival. (B) 
Notable differences between 28-day and 1-year survival are the weaker association between 
both vasopressor use and ventialtion with survival and a signficant assoication between white 
race and survival.   
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Legend to the tables 
Table 1: Overview of patient characteristics and outcomes. Patients with cancer had higher 
comorbidity scores, similar clinical severity scores, on average received less invasive treatment 
and had higher 28-day and 1-year mortality. All differences between the subgroups where 
overall statistically significant with p-values<0.001. DNR=Do not resuscitate, SOFA: Sepsis related organ 
failure assessment, OASIS: Oxford acute severity of illness score, APACHE-III: Acute physiology and chronic health 
evaluation score. If not indicated differently, values refer to the mean (Standard Deviation). 
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Supplementary material 
Supplementary table 1: trends in cancer patient admission, characteristics and outcomes 
by year of admission. The number of oncological cases admitted to the ICU increased by 
238% over the 10-year period. Clinical severity scores remained approximately unchanged, 
while use of vasopressors and ventilation decreased significantly. The mean Elixhauser 
comorbidity score increase steadily over the study period. Both 28-day and 1-year mortality 
decreased over time, with the 28-day mortality (-31%) decreasing faster than 1-year mortality (-
18%). 
 
Supplementary figure 1: (A) 28-days and (B) 1-year mortality rates by cancer type and 
SOFA-scores. SOFA scores were strongly associated with mortality across all cancer 
subtypes. Overall, cancer patients had worse outcomes compared to non-cancer patients with 
similar SOFA scores. Patients with high SOFA-scores (≥11) and a connective tissue malignancy 
(including breast cancer, N=2) and genitourinary cancer (N=7) had a 100% probability of dying 
at 28-days. Similarly, patients with gastrointestinal cancer (N=49) and leukemia (N=23) and high 
SOFA-scores (≥11) had a close to 100% probability of dying at 1-year.  
 
Supplementary figure 2: Results of the multivariate model for (A) 28-day and (B) 1-year 
mortality for the whole cohort. (A) After adjusting for other covariates, DNR at admission 
(OR=3.69) was the strongest predictor of 28-day mortality, followed by any use of mechanical 
ventilation and presence of any malignancy. Year of admission was a strong protective factor, 
with mortality rates decreaseing by 6% every year. With each year increase in age at admission, 
the odds of dying within 28 days and 1 year increased by 2%. A one point increase in APACHE-
III scores was closer asscoiated with a higher increase in the odds of dying within 28 days (4%) 
than 1 year (2%).  
 
Variables 
Without 
cancer 
Hematologic 
Malignancy 
Solid 
malignancy 
Hematologic and 
solid cancer 
Number of cases 36,366 1,100 3,953 49 
Age at admission, years 63.8 (17.8) 65.3 (16.4) 65.8 (13. 6) 69.9 (12.7) 
DNR at admission (%) 1819 (6.0) 72 (8.2) 297 (9.5) 3 (7.7) 
White race (%) 26074 (71.7) 851 (77.4) 2979 (75.4) 39 (79.6) 
Length of stay ICU, days 4.59 (6.09) 5.38 (7.15) 4.19 (5.30) 4.00 (3.34) 
Length of stay Hospital, days 9.3 (8.7) 14.7 (15.2) 10.1 (8.3) 11.0 (10.0) 
Use of ventilation (%) 18181 (50.0) 470 (42.7) 1699 (43.0) 20 (40.8) 
Use of vasopressors (%) 12428 (34.2) 369 (33.5) 990 (25.0) 11 (22.4) 
Elixhauser score 8.8 (11.1) 17.6 (11.8) 19.4 (13.0) 23.9 (12.4) 
SOFA score 3.3 (2.5) 4.6 (3.0) 3.3 (2.7) 3.4 (2.9) 
APACHE-III score 42.0 (19.4) 50.4 (22.1) 44.5 (20.3) 46.7 (23.3) 
OASIS score 31.4 (9.0) 32.5 (9.0) 31.2 (9.5) 31.2 (9.9) 
28-day Mortality (%) 4640 (12.8) 305 (27.7) 1143 (28.9) 13 (26.5) 
1-year Mortality (%) 8378 (23.0) 579 (52.6) 2420 (61.2) 29 (59.2) 
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